K033430

NOV - 7 2003

Summary of Safety and Effectiveness

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR § 807.93

Submitter	Implant Innovations, Inc. 4555 Riverside Palm Beach Gardens, FL 33410
Contact	Tamara Nelson International Regulatory Affairs Specialist Implant Innovations, Inc. 4555 Riverside Palm Beach Gardens, FL 33410 Tel. 561-776-6923 Fax. 561-776-6852 Email tnelson@3implant.com
Date Prepared	October 24, 2003
Device Name	*3i* TG OSSEOTITE® Wide Implants
Classification Name	Endosseous Dental Implant
Device Classification	Class III Dental Devices Panel 21 CFR § 872.3640
Predicate Devices	TG OSSEOTITE® Dental Implants K972444 OSSEOTITE® IOL Implants K031632
Performance	Performance standards have not been established by the FDA under Section 514 of the Federal Food, Drug and Cosmetic Act.
Device Description	The *3i* TG OSSEOTITE® Wide Implants are trans-gingival implants designed with an internal morse-taper. The wider dimension of the seating surface provides a realistic size proportion of a natural tooth of the posterior area.

Indications for Use	The *3i* TG OSSEOTITE® Wide Implants are indicated for surgical placement in the upper or lower jaw to provide a means for prosthetic attachment.
Technological Characteristics	The *3i* TG OSSEOTITE® Wide Implants contain features and functions which are similar to the currently available TG OSSEOTITE® Implants.
Conclusion	The *3i* TG OSSEOTITE® Wide Implants are substantially equivalent to the legally marketed TG OSSEOTITE® Implants.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

NOV - 7 2003

Ms. Tamara Nelson
International Regulatory Affairs Specialist
Implant Innovations, Incorporation
4555 Riverside Drive
Palm Beach Gardens, Florida 33410

Re: K033430
Trade/Device Name: 3I TG Osseotite Wide Implants, Models TG685, TG610, TG611, TG613
Regulation Number: 872.3640
Regulation Name: Dental Implant
Regulatory Class: III
Product Code: DZE
Dated: October 27, 2003
Received: October 28, 2003

Dear Ms. Nelson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

for Chiu Lin, Ph.D.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K033430

Device Name: ***3i*** TG OSSEOTITE® Wide Implants

Indications for Use:

3i dental implants are indicated for surgical placement in the upper or lower jaw to provide a means for prosthetic attachment.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Anesthesiology, General Hospital,
Infection Control, Dental Devices

510(k) Number: K033430

Prescription Use: ✓ OR Over the Counter Use: _____
(Per 21 CFR 801.109)